Company Presentation

Mitsubishi Tanabe Pharma CorporationBusiness Development

Acceleratinggrowth through innovation with you.

November 15, 2017

2

Shaping

(Store front, 1855)

Seeking new opportunity

in change for over 330 years.

1678Since Headquarters

Osaka, Japan

US$ 4,239MNet sales

(FY2016, JPY 100/US$)

7,280Employees

(Consolidated, March, 2017)

1,714Medical Reps/Sales Force

(May, 2016)

14 countries

Global network

(April, 2017)

the History of Medicationsince the 17th Century

3

•Clinical testing•Pharmaceutical ingredients •Capsules

•Medical materials•Reverse osmosis water purification systems

•Medical gases•Water-18O for PET cancer diagnosis

Net sales:

US$33,761 M

MCHC Group Power – Our Key to Unlocking an Expanded World of Health Care

Health care sales:

US$5,470M

“Ranging from Therapeutics to Healthcare”

(FY2016, JPY 100/US$)

•Pharmaceuticals•Vaccines

MCHC

Creatingvalue with skill and speed with you.New value creation is a process founded on our cumulative experience

and expertise, and our commitment to bettering the health of

people around the world. In order to be the first to develop,

produce and deliver original pharma solutions, working with skill

and speed together with complementary partners is essential.

4

5

Blazing a Trail with First-in-class Drug Discovery

ALS: Amyotrophic lateral sclerosis S1P: Sphingosine-1-phosphate“The Pharmaceutical Society of Japan Award for

Drug Research and Development”

Awards (1988, 2003, 2012, 2014)

Canagliflozin

Type 2 diabetes (U.S.A., 2013)

SGLT2 inhibitor

Invokana®/Canaglu®Fingolimod

Multiple sclerosis (U.S.A., 2010)

S1P receptor modulator

Gilenya®/Imusera®

Acute stroke (Japan, 2001)ALS (Japan, 2015)NDA approved for ALS (U.S.A., 2017)

Free radical scavenger

EdaravoneRadicut®/Radicava™

Calcium channel blocker

DiltiazemHerbesser®

Approved in more than 100 countries

World First

World First

World First

Japan Origin

6

Succeeding on the Global Stage with Strong Partners

(2015)70 countriesoverApproved

in

US$1,270MSales(2016) US$3,109M (2016)

Licensed to JanssenCo-marketed in Japan with

Daiichi Sankyo

Licensed to Novartis AG

Sales

Approved in

Canaglu® (Japan) Imusera® (Japan)

(2015)80 countriesover

7AS: Ankylosing spondylitis CD: Crohn’s disease RA: Rheumatoid arthritis UC: Ulcerative colitis

Maximizing the Potential of Drugs through Deep Links in the Medical Community

2002 2004 2006 2008 2010 2012 2014

JPY 100/US$

RA

Behcet‘s disease

CD maintenance

Psoriasis

AS, UC

Launch ofSimponi®

Shorter infusion time (All indications)

Behcet's disease with special lesions

Kawasaki disease

Dosage/Usage*NHI drug price basis

Additional indications

US$1B*

Sales

Launch of Remicade®for CD

in 2013

CD: dose escalationRA: dose

escalation

2016

Psoriasis: dose escalation

2018

CD: shorter administration interval

Pioneeringnew frontiers with you.We are constantly honing our skills

and expanding our repertoire.

As we extend our expertise in our core competency,

we are also blazing trails in new frontier through

the orchestration of talent and assets.

8

9

Partnering in Four Prioritized Fields of MTPC Proven Expertise

CNS: Central nervous system, VLP: Virus-like particles, *: Additional indications

Italic: In-licensed products

Autoimmune & Inflammatory

Remicade®, Simponi®, Imusera®

Diabetes & Kidney

Canaglu®, Tenelia®,Canalia®, Kremezin®

CNS

Lexapro®, Radicut®/RadicavaTM

Vaccine

Tetrabik®, Influenza vaccine, etc.

MT-1303, MT-5547, MT-5373

MP-214, MT-5199

MT-2355, VLP vaccines

MT-3995, MT-6548, Canaglu®*

Regenerative medicine

10

Partnering in Challenging Fields at the Frontier of Therapeutics

• Established “Future Design Department” to implement initiatives beyond the pharmaceuticals.

• In-licensing Invossa®, a cell therapy product for knee osteoarthritis in 2016.

• Joint research with MedImmune, LLC on oncology antibody-drug conjugates started in 2015.

• Joint research with Covagen AG on bispecificantibodies started in 2013.

Biologics

Mappingthe path to value creation with you.We find partners who share and complement our vision,

and together, we grow and overcome the challenges

of these changing times.

Together we discover new value through

new drugs and indications.

11

12

Business Development TeamCovering Markets Worldwide

Around the world, members of our Business Development team are looking forward to hearing from you.

Dr. Shigekazu Nakajima(General Manager)

Business DevelopmentJapan (MTPC)

Business DevelopmentEurope (MTPE)Mr. Masami Yuhara(General Manager)

Dr. Eiji Tanaka (Head of GBD,

Executive Officer)

Global Business Development

(GBD)

Dr. Hiroshi Kawai(Vice President)

Business Development U.S.A. (MTHA)

Business DevelopmentEurope (MTPE)

Business DevelopmentJapan (MTPC)

Business DevelopmentU.S.A. (MTHA)

Mr. Tetsuro Iwata (Group Manager)

Dr. Shigekazu Nakajima(Group Manager)

Mr. Yuzo Hanasaki(Group Manager)

*Dr. Nakajima concurrently holds two titles

13*1 Total as of FY2020 *2 Total investment through FY2020

MT Pharma America, Inc.(2016 ̶ )

Establishing a Sales Force and Bringing New Drugs to the U.S. Market

Grow business in the U.S.(Expected to reach US$800M*1) JPY 100/US$

Radicava™launched

in the U.S.

(Strategic investment: over US$2B*2)

In-licensing

In-house products

14

Demonstrated efficacy in delaying the progression of functional damage due to ALS.

Designated as orphan drug (FDA/EMA)

2015ALS indication

approved in Japan

ALS

FRS-

R(c

han

ge o

ver

24

wee

ks)

Edaravone(n=68)

Placebo(n=66)

0

-1

-2

-3

-4

-5

-6

-7

-8

-9

P value: 0.0013

Radicava™the Catalyst for Our Pipeline Expansion

Radicava™(Edaravone)

Aiming for

expansion of product pipelines in the U.S.

ALS: Amyotrophic lateral sclerosis ALSFRS-R: ALS functional rating scale-revised

Launched in the U.S. in August, 2017

15

Sustained growth of the US businessExpanding

Step 1: RadicavaTM

launch

Step 2: Acquisition of NeuroDerm

Step 3: Sustained growth of the U.S. business

In the U.S. market : Establish a presence in specialized fields

・MT-8554 ・M&A or in-license

CNS

Autoimmune

・MT-1303 ・MT-7117・M&A or in-license

Expected to reach $800M ofthe U.S. revenue in FY2020

JPY 100/US$

16

NeuroDerm- Pipeline Products

17

ND0612 PK Results

18

Our Mission Why we are here in UK?

To acquire pipeline products from EU-based companies ; -

– in specialty areas for US marketPreferably late stage CNS/orphan products (after POC)

–hospital products for EU marketEither marketed or close-to-market products

– in autoimmune, metabolic and renal, CNS and vaccines for Japan/Asian market

19

Growing Together through Open Innovation

Partner

“Open Innovation”

MTPC

is the flexibility of a diversity of partnership structures

Joint research

Co-investment

In-license

Co-promotion Funds

Territory Co-marketing

Co-development

M&AOut-license

etc.

The First to Deliver Original Value

Meeting the unmet medical needs, discovering new indications,

and bringing pharma solutions to new markets,

we are research driven with global aspirations

and the speed and agility to not

only keep pace but lead the times.

20

Appendix

21

22

EUROPE

Sales

Business &

Marketing

Product

Quality

Assurance

HR &

Administration

Accounting

& Finance

Corporate

Management

Medical

Affairs

Drug Safety

Drug

Regulatory

Clinical

Development

MTPE- Established Functions in Europe

By MTPE

By MTPD

As of 31.03.2015

By Partner

Argatroban is marketed under various brand names.

MTPE- Argatroban Available in Europe

24

UK, Germany,

Austria,

Switzerland

EU 5 countries

+

Small neighbor

countries

FY 2015

FY 2020

Sales infrastructure is established

Sales infrastructure under 5 year plan

Next priority

Mid-Term Corporate Plan in Europe

25

Current Pipelines - Overview

As of August 21, 2017

*Additional indication, new formulation, or change in dosage

Phase 2 Phase 3 NDA filed

Autoimmune &

Inflammatory

Diabetes & Kidney

Vaccine

Imusera®*(MNT)(fingolimod)

Vaccine (CA)(H5N1 influenza)

Vaccine (US/CA)(Seasonal influenza)

MT-2355 (JP)(combined vaccine)

MT-0814 (JP)

MT-1303 (JP/EU/US)(amiselimod)

Vaccine (CA)(H7N9 influenza)

GB-1057 (US)(human serum albumin)

MP-513 (EU) (teneligliptin)

CNSMP-214 (JP/Asia)

(cariprazine)

MT-5199 (JP)(valbenazine)

MT-8554 (EU)

MP-124 (US)

MP-157 (EU)

MT-3995 (US)

MP-513 (ID)(teneligliptin)

MP-513 (US)(teneligliptin)

TA-7284*(MNT)(canagliflozin)

Phase 1

MT-7117 (EU)

MNT: Multinational trial

Other

MT-1303 (JP/EU)(amiselimod)

CNS: Central nervous system Italic: In-licensed product

MT-6548 (JP)(Vadadustat)

MP-513 (CN)(teneligliptin)

MT-4129 (EU)

MT-3995 (JP/EU)

Moved forward since last update May 21, 2017.

Novastan® (CN)(argatroban)

MT-2990 (EU)

Text in red

MT-5547 (JP)(fasinumab)

26

Current Pipelines

ProductMechanism(Indications)

Region Stage Origin/Licensee

Imusera®

(fingolimod)

S1P receptor functional antagonist(Chronic inflammatory demyelinating polyneuropathy)

Japan, US, Europe and others

Phase 3(MNT)

In-house / Novartis (co-development in Japan, out-licensed for overseas)

MT-1303(amiselimod)

S1P receptor functional antagonist(Multiple sclerosis) Europe Phase 2

In-house(Psoriasis) Europe Phase 2

(Crohn’s disease) Japan, Europe Phase 2

(Inflammatory/Autoimmune) Japan, Europe, US

Phase 1

MT-7117 (Inflammatory/Autoimmune) Europe Phase 1 In-house

MT-2990 (Inflammatory/Autoimmune) Europe Phase 1 In-house

MT-5547 anti-NGF monoclonal antibody (osteoarthritis) Japan Phase 2/3 from Regeneron (US)

MP-214(cariprazine)

Dopamine D3/D2 receptor partial agonist(Schizophrenia) Japan, Asia Phase 2b/3 from Gedeon Richter

(Hungary)

MT-210 5HT2A/ Sigma 2 receptor antagonist(Schizophrenia) Europe Phase 2 In-house / Minerva

Neurosciences(US)

Wf-516 Multiple mechanisms on several receptors*(Depression) Europe Phase 2 In-house / Minerva

Neurosciences(US)

MP-124 PARP inhibitor(Acute ischemic stroke) US Phase 1 In-house

MT-8554 (Nervous system, etc.) Europe Phase 1 In-house

MT-5199(valbenazine)

Vesicular monoamine transporter type 2 (VMAT2) inhibitor (Tardive dyskinesia)

Japan Phase 2/3 from Neurocrine Biosciences (US)

Text in red: In-licensed product

Au

toim

mu

ne

&

Infl

amm

ato

ryC

NS

MNT: Multinational trial* SSRI (Selective serotonin reuptake inhibitors), 5-HT1A, dopamine transporter and α1A/B-Adrenergic receptors

As of August 21, 2017

27

Current Pipelines

Text in red: In-licensed product

ProductMechanism(Indications)

Region Stage Origin/Licensee

TA-7284(canagliflozin)

SGLT2 inhibitor(Diabetic nephropathy)

Japan, US, Europe and others

Phase 3(MNT)

In-house / Sponsor: Janssen Research & Development (US)

(Type 1 Diabetes Mellitus) US, Canada Phase 2In-house / Janssen Pharmaceuticals (US)FDC with phentermine

(Obesity) US Phase 2

MP-513(teneligliptin)

DPP-4 inhibitor(Type 2 Diabetes Mellitus)

Indonesia Filed

In-houseChina Phase 3

Europe Phase 2

US Phase 1

MT-3995

Selective mineralocorticoid receptor antagonist (Diabetic nephropathy)

Europe, Japan Phase 2

In-houseUS Phase 1

(Non-alcoholic steatohepatitis: NASH) Japan Phase 2

MT-6548(vadadustat)

Hypoxia inducible factor prolyl hydroxylase (HIF-PH) inhibitor(Anemia related to chronic kidney disease)

Japan Phase 2 from Akebia (US)

MT-2355Combined vaccine (Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and Hib infection in infants)

Japan Phase 3 Co-developed with BIKEN foundation (Japan)

Influenza vaccine

Plant-based VLP vaccine(Prophylaxis of H5N1 influenza) Canada Phase 2 In-house

(Prophylaxis of seasonal influenza) US, Canada Phase 2 In-house

(Prophylaxis of H7N9 influenza) Canada Phase 1 In-house

Dia

bet

es

& K

idn

ey

Vac

cin

e

MNT: Multinational trialFDC: fixed dose combination

As of August 21, 2017

28

Current Pipelines

ProductMechanism(Indications)

Region Stage Origin/Licensee

Novastan®

(argatroban)Selective antithrombin agent(Acute cerebral infarction) China Filed In-house

MT-4580Ca sensing receptor agonist(Secondary hyperparathyroidism in chronic kidney disease patients on maintenance dialysis)

Japan FiledIn-house/ Kyowa Hakko Kirin (Japan)

Y-39983 ROCK (Rho kinase) inhibitor(Glaucoma) Japan Phase 2 In-house/ Senju

Pharmaceutical (Japan)

MCC-847(masilukast)

Leukotriene D4 receptor antagonist(Asthma) Korea Phase 2 In-house/ SAMA Pharma

(Korea)

Y-803 Bromodomain inhibitor(Cancer) Europe, Canada Phase 2 In-house/ Merck (US)

GB-1057(recombinant human serum

albumin)

Blood and blood forming organs US Phase 1 In-house

MP-157 Angiotensin type 2 receptor agonist(Hypertension) Europe Phase 1 In-house

MT-0814 CC Chemokine receptor 3 (CCR3) antagonist(Age-related macular degeneration) Japan Phase 1 In-house

sTU-199(tenatoprazole) (Alimentary tract and metabolism) Europe Phase 1 In-house/ Negma/Sidem

(France)

MT-4129 (Cardiovascular system) Europe Phase 1 In-house

Oth

ers

As of August 21, 2017

29

MTPC’s Recent Alliance Activities

In-licenseOut-licenseR&D collaboration

Strategic collaboration & Licensing agreement

withMedImmune

Development of antibody-drug

conjugates for various cancers

(September 23, 2015)

Worldwide patent andknow-how transfer

with Amgen

TA-8995 (CETP inhibitor) for dyslipidemia

(September 16, 2015)(September 29, 2015)

with Regeneron

Pharmaceuticals

Fasinumab (anti-NGF antibody) for

musculoskeletal pain

Collaboration agreement

CETP: Cholesteryl ester transfer proteinHIF-PH: Hypoxia-inducible factor prolyl hydroxylaseIL: interleukin, NGF: Nerve growth factor, FDC: fixed dose combination

Strategic alliance

withDaiichi Sankyo

MT-2412 (DPP-4 inhibitor & SGLT2

inhibitor, FDC)for type 2 diabetes

(March 29, 2017)

License agreement

with Kolon Life Science

Invossa® (cell therapy product) for knee

osteoarthritis

(November 1, 2016) (October 4, 2016)

with Teikoku Seiyaku

Rupatadine, an oral anti-allergy

agent

Basic agreement for Sales

Co-promotion agreement

with Janssen

Pharmaceutical

Stelara® (anti-IL-12/23 antibody) for Crohn’s

disease

(February 3, 2017)

Collaboration agreement

withAkebia

TherapeuticsVadadustat (HIF-PH

inhibitor) for anemia related to chronic

kidney disease(December 15, 2015)

30

MTPC Facts: Financial Summary

(JPY 100/US$)

Sales (consolidated)

R&D expenses

2013 2014 2015 2016 (FY)

2013 2014 2015 2016 (FY)

(M US$)

Operating income

(M US$)

591671

949/1,069*945*

704 696753/646

647

IFRS

*core operating income

(M US$) 4,317/4,257 4,239

4,127 4,151

2013 2014 2015 2016 (FY)

GAAP: Generally Accepted Accounting Principles, IFRS: International Financial Reporting Standards

Japan GAAP

MTPC Facts: Business Portfolio

Sales by business

Net sales

US$4,239M(FY2016)

Domestic ethical drugs74.1%

OTC drugs0.8%

Royalty, etc.19.4%

Others0.3%

Overseas ethical drugs5.3%

(JPY 100/US$)

Sales by region

Net sales

US$4,239M(FY2016)

Domestic 75.6%

Overseas 24.4%

31

Sales by treatment field (Japan)

US$3,439M(FY2016)

Autoimmune & InflammatoryUS$910M (26%)

Source: IMS MIDAS DATA

VaccineUS$510M (15%)

Cardiovascular SystemUS$400M (12%)

Respiratory SystemUS$350M (10%)

Alimentary SystemUS$160M (5%)

Metabolic & KidneyUS$150M (4%)

OthersUS$300M (9%)

Autoimmune & InflammatoryRemicade®, Simponi®, Imusera®

Neurology & CNSRadicut®, Ceredist®, Depas®

Lexapro®, Sermion®

VaccineTetrabik®, Influenza, Varicella

Cardiovascular SystemMaintate®, Tanatril®

Herbesser®, Anplag®, Liple®

Respiratory SystemTalion®, Theodur®

Alimentary SystemUrso®, Omeprazon®

Metabolic & KidneyKremezin®, Tenelia®, Canaglu®

Major products

32

MTPC Facts: Sales by Treatment Fields

Neurology & CNSUS$650M (19%)

(JPY 100/US$)

・London, UK・Düsseldorf, Germany・Vienna, Austria・Zürich, Switzerland・Le Plessis-Robinson, France

33

MTPC’s Global Presence

ResearchSales ProductionDevelopment Venture CapitalOffice

Europe

・Osaka & Tokyo・Yokohama, Toda & Osaka・Osaka, Onoda & Yoshitomi・15 branches

Japan

・Jersey City, U.S.A.・San Diego, U.S.A.・Boston, U.S.A.・Quebec, Canada

North America

Asia

・Taipei, Taiwan・Jakarta, Indonesia・Seoul, Korea・Bangkok, Thailand

・Tianjin, China・Beijing, China・Shanghai, China・Singapore

5

Development

34

North America Business Network

ResearchSales

Development Venture Capital

Office

MPH: MP Healthcare Venture Management, Inc.MTDA: Mitsubishi Tanabe Pharma Development America, Inc.MTHA: Mitsubishi Tanabe Pharma Holdings America, Inc.

5 MTDA (NJ)

Sales

MTPA: MT Pharma America, Inc.TRL: Tanabe Research Laboratories U.S.A., Inc.

12

34

68TRL (CA)

Research

1

U.S. business control

MTHA (NJ)

2

Strategic investment

MPH (MA)3

Medicago Inc.(Canada, NC)

MTPA (NJ)

4Canada business control

MTPC Holdings Canada, Inc. (Canada)

8

7

6, 7

Name MP Healthcare Venture Management, Inc. (MPH)

Location 33 Arch Street, Boston, MA 02110, U.S.A.

Established dateAugust, 2006 (Boston Office opened in February 2007)

Fund size US$100M

Shareholder MTPC 100%

MPH's role for MTPC Strategic investor

Companies of MPH's interest

•Mainly seed or growth stage (privately owned) biotechs.•Principally North American or European-based companies.•Promising drug/vaccine candidates or state-of-the-art technology platform.

Contact MPHEmail: MPH-WEB@mp-healthcare.comWebsite: http://www.mp-healthcare.com/

35

MP Healthcare Venture Management, Inc.- Overview

36

MP Healthcare Venture Management, Inc.- Portfolio Companies

Advancing therapeutic programs for renal diseases including acute kidney injury (AKI) and chronic kidney disease (CKD)November, 2012*

Developing unique RNA-based immuno-therapeutics targeting RIG-I for the treatment of cancer and viral diseasesAugust, 2015*

Discovery and development of innovative microRNA-targeting therapies for fibrosis, cancer, cardiovascular disease and ALS November, 2015*

Improved therapeutic antibodies and antibody fragments based on its ability to introduce antigen-binding sites into the Fc region of antibodiesOctober, 2009*

Active portfolio * MPH participated Portfolio archives

April, 2017*

Discovery of novel therapeutics to target metalloprotein by using a novel drug discovery platform

37

Medicago Inc. - Overview

Name Medicago Inc.

LocationHQ, R&D: Quebec City, CANADAcGMP facility: Research Triangle Park, NC, U.S.A.

Shareholder MTPC 60%

Focus Vaccines & Protein-based pharmaceuticals

Manufacturing Technology

Transient expression in plant leaf(Nicotiana benthamiana)

Vaccine Technology Virus-like particles

Employees 265 (Quebec 172 / NC 93)

Product Pipeline(Vaccine)

Pandemic Flu (H5): Phase IISeasonal Flu (Quadrivalent): Phase IIRotavirus: Preclinical

Contact Medicago Website: http://www.medicago.com/

38

Tanabe Research Laboratories U.S.A., Inc. - Overview

Name Tanabe Research Laboratories U.S.A., Inc. (TRL)

Location 4540 Towne Centre Court, San Diego, CA 92121, U.S.A.

Established date November, 1990

Shareholder MTPC 100%

TRL's role for MTPC Drug discovery

Business activities

• Discover and develop biological drug candidates for the therapy of serious diseases with unmet needs.

• TRL’s effort is directed towards oncology research using antibody and other biological methods to target specific molecules on cancer cells (and soluble factors), as well as investigating new methods for modulating cancer cell functions.

Contact TRL Website: http://www.trlusa.com/

39

NeuroDerm Ltd. - Overview

Name Neuroderm Ltd.

Location3 Pekeris Street, Ruhrberg Science Bldg., Bell Entrance,Rabin Science Park, Rehovot 7670212, Israel

Shareholder MTPC 100%

Role for MTPC Expansion of neurology pipeline portfolio

Business activities

• Develops novel formulation technology and continuous SC/patch pump combinations for CNS disorders including Parkinson’s disease

• The first company to develop liquid levodopa and carbidopa

Product Pipeline・ND0612 (Advanced Parkinson’s Disease) : Phase III・ND0701 (Severe Parkinson’s Disease) : Phase II・ND0801 (CNS Disease, Cognition disorders) : Phase II

Contact Neuroderm

Website: http://neuroderm.com/

SC: subcutaneous administrationCNS: Central nervous system

40

Transaction Overview

41

Company Overview

42

Key Strengths of NeuroDerm

43

ND0612 Profile

44

ND0612 Efficacy

45

ND0612 Development Timelines

46

Overview of Parkinson’s disease

47

Depression

Lexapro

Anxiety

Depas

Parkinson’s disease

Parkin

Selenica

Epilepsy

Tardive dyskinesia

MT-5199

Radicut

Acute stroke

Schizophrenia

Impromen

MP-214

Multiple sclerosis

Imusera/Gilenya

ALS

Radicut/RadicavaTMCeredist

Spinocerebellardegeneration

Strengthening CNS Franchise

CNS: Central nervous system Italic: In-licensed productALS: Amyotrophic Lateral Sclerosis

48

Preventing Infectious Diseases

Vaccines (JPY 100 /US$)

Tetrabik®

Combination vaccinePertussis, Diphtheria, Tetanus and Polio

Domestic Sales : $95M

Biken HA®

Influenza HA VaccineInfluenza

Domestic Sales : $138M

Biken®

Varicella vaccineVaricella

Domestic Sales : $64M

MT-2355

Combined VaccineProphylaxis of pertussis, diphtheria, tetanus, poliomyelitis and Hibinfection in infants

Phase 3 (JP)

BIKEN Corporation, a joint venture with BikenFoundation and MTPC, started their operation of vaccine manufacturing on September 1st, 2017.

Hib: Haemophilus Influenzae b

49

Canaglu

Tenelia

CanaliaFDC of Tenelia/Canaglu

(NDA filed)

Type 2 diabetes

New Initiatives in Diabetes and Kidney Field

Kremezin

(for chronic renal failure)

MT-6548 (for renal anemia)

Nephropathy

Diabetes & Kidney

FDC: fixed dose combination, MNT: multi national trial

Diabetic Nephropathy

TA-7284(Canagliflozin)

(MNT)

MT-3995

Strategic Alliance with

Daiichi Sankyo

for Tenelia, Canaglu and Canalia to contribute to the treatment of diabetes in Japan.

49

CNS

50

Various Partners for In-licensing

Metabolic, Renal & CVMaintate® (bisoprolol)

Grtpa® (alteplase)

Sermion® (nicergoline)

Kremezin®

Pitavastatin

MT-6548

Modiodal®(modafinil)

MP-214 (cariprazine)

MT-5199

Remicade® (infliximab)

Simponi® (golimumab)

Stelara® (ustekinumab)

Talion® (bepotastine)

Methotrexate

MT-5547

Invossa®

Rupatadine

Omeprazon®

Valixa®

Zione®

P Guard®

Pazucross®

Clearnal®, Doral®

Collategene®

MT-2301 (Hib vaccine)

Telavic® (telaprevir)

Inflammation & Respiratory

Others

CNS: Central nervous system

CNS

51

Various Partners for out-licensing

Metabolic, Renal & CV

Immunology, Inflammation & Respiratory

Others

Fingolimod (FTY720)

Bepotastine

MCC-847

Difluprednate

ArgatrobanCanagliflozin (TA-7284) Teneligliptin (MP-513) Herbesser® (diltiazem) Tanatril® (imidapril) MT-4580TA-8995

MT-210, Wf-516

Rize®

Avanafil

Surfacten®

sTU-199

Anplag®, Zione®

Depas®, Serotone®

Pazucross®

Bepotastine, Ecabet,

Y-39983

Ecabet

Y-803

CNS: Central nervous system

52

Nu

mb

er

of

MR

24842400

23002200 2200

1900 1900

1750 1714 1698

1450 1430 1400

Reference : Monthly Medical information express (2016)

MR force ranking in JP market